Due to customer demand, we’re introducing a new product line at ISSX in Portland
We are pleased to showcase our new product line, recombinant human UGTs, manufactured using insect cell technology, at the ISSX event in Portland, Oregon later this month.
We’ve been asked by our customers when we would launch UGTs to complement our extensive selection of human enzymes. To meet this demand, we set up an alternative expression system in-house, using Sf9 insect cells which we infect with recombinant baculovirus. This allows for a robust and reliable enzyme and ensures the high quality that customers expect from Cypex products.
We will release UGTs 1A1, 1A3, 1A7, 1A8, 1A9 and 1A10 at the ISSX event this month, with UGTs 1A4 and 1A6 following later this year. This panel of eight UGT enzymes has been developed in our laboratory in Dundee, Scotland, by our lead scientists Michael Voice and Michael Pritchard.
If you would like to find out more information about our extensive range of products and services, please visit www.cypex.co.uk, or if you are attending the ISSX event in Portland please come and say hello to us at booth 113.